MA50255A - Protéines de liaison à nkg2d, cd16, et molécule-1 semblable à la lectine de type c (cll-1) - Google Patents

Protéines de liaison à nkg2d, cd16, et molécule-1 semblable à la lectine de type c (cll-1)

Info

Publication number
MA50255A
MA50255A MA050255A MA50255A MA50255A MA 50255 A MA50255 A MA 50255A MA 050255 A MA050255 A MA 050255A MA 50255 A MA50255 A MA 50255A MA 50255 A MA50255 A MA 50255A
Authority
MA
Morocco
Prior art keywords
nkg2d
cll
lectin
molecule
binding proteins
Prior art date
Application number
MA050255A
Other languages
English (en)
Inventor
Gregory P Chang
Ann F Cheung
William Haney
Bradley M Lunde
Bianka Prinz
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of MA50255A publication Critical patent/MA50255A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA050255A 2017-09-14 2018-09-13 Protéines de liaison à nkg2d, cd16, et molécule-1 semblable à la lectine de type c (cll-1) MA50255A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762558510P 2017-09-14 2017-09-14

Publications (1)

Publication Number Publication Date
MA50255A true MA50255A (fr) 2021-05-26

Family

ID=65723086

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050255A MA50255A (fr) 2017-09-14 2018-09-13 Protéines de liaison à nkg2d, cd16, et molécule-1 semblable à la lectine de type c (cll-1)

Country Status (14)

Country Link
US (1) US20200277384A1 (fr)
EP (1) EP3681532A4 (fr)
JP (1) JP2020534269A (fr)
KR (1) KR20200051789A (fr)
CN (1) CN111432832A (fr)
AU (1) AU2018331412A1 (fr)
BR (1) BR112020005078A2 (fr)
CA (1) CA3075857A1 (fr)
EA (1) EA202090718A1 (fr)
IL (1) IL273206A (fr)
MA (1) MA50255A (fr)
MX (1) MX2020002880A (fr)
SG (1) SG11202002298PA (fr)
WO (1) WO2019055677A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018148445A1 (fr) 2017-02-08 2018-08-16 Adimab, Llc Protéines de fixation multi-spécifiques destinées à l'activation de cellules tueuses naturelles et leurs utilisations thérapeutiques pour traiter le cancer
KR20240060739A (ko) 2017-02-20 2024-05-08 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
CA3237846A1 (fr) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Domaines variables d'anticorps ciblant le recepteur nkg2d
WO2019178364A2 (fr) * 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Molécules multifonctionnelles et utilisations associées
JP7453971B2 (ja) * 2018-10-19 2024-03-21 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Ｎｋエンゲージャー分子およびその使用方法
US20220119534A1 (en) * 2020-05-06 2022-04-21 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and clec12a
JP2024516645A (ja) * 2021-04-26 2024-04-16 ミレニアム ファーマシューティカルズ， インコーポレイテッド 抗ｃｌｅｃ１２ａ抗体及びその使用
CN113817065B (zh) * 2021-09-06 2023-04-18 深圳市乐土生物医药有限公司 一种抗her2的多肽及其用途
CN117106086A (zh) * 2022-08-09 2023-11-24 合源康华医药科技(北京)有限公司 一种cll1抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115198A1 (en) * 2001-02-28 2004-06-17 Fred Hutchinson Cancer Research Center Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
EP1909832A4 (fr) * 2005-06-29 2010-01-13 Univ Miami Proteine de fusion anticorps-ligand de cellule immunitaire pour le traitement du cancer
EP2014680A1 (fr) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Dérivés d'anticorps bi-spécifiques ou tri-spécifiques trivalents, recombinants, à simple chaîne
CN101945893B (zh) * 2007-12-14 2015-02-25 诺沃-诺迪斯克有限公司 抗人nkg2d抗体及其用途
US10865233B2 (en) * 2008-12-18 2020-12-15 Dana-Farber Cancer Institute, Inc. NKG2D-fc for immunotherapy
US9163090B2 (en) * 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
DK2900694T3 (en) * 2012-09-27 2018-11-19 Merus Nv BISPECIFIC IGG ANTIBODIES AS T-CELL ACTIVATORS
ES2847155T3 (es) * 2016-01-21 2021-08-02 Novartis Ag Moléculas multiespecíficas que fijan como objetivo CLL-1
CA3054738A1 (fr) * 2017-02-27 2018-08-30 Dragonfly Therapeutics, Inc. Proteines de liaison multispecifiques ciblant un antigene carcinoembryonnaire

Also Published As

Publication number Publication date
BR112020005078A2 (pt) 2020-10-13
AU2018331412A1 (en) 2020-03-26
EP3681532A4 (fr) 2021-09-01
CA3075857A1 (fr) 2019-03-21
EA202090718A1 (ru) 2020-07-01
EP3681532A1 (fr) 2020-07-22
CN111432832A (zh) 2020-07-17
WO2019055677A1 (fr) 2019-03-21
IL273206A (en) 2020-04-30
MX2020002880A (es) 2020-10-01
US20200277384A1 (en) 2020-09-03
KR20200051789A (ko) 2020-05-13
JP2020534269A (ja) 2020-11-26
SG11202002298PA (en) 2020-04-29

Similar Documents

Publication Publication Date Title
MA50255A (fr) Protéines de liaison à nkg2d, cd16, et molécule-1 semblable à la lectine de type c (cll-1)
MA47508A (fr) Protéines de liaison à cd33, nkg2d et cd16
MA51291A (fr) Protéines de fusion il-2 fc modifiées
SG11202010237RA (en) Fusion protein binding to cd47 protein and application thereof
MA47465A (fr) Protéines fixant le bcma, le nkg2d et le cd16
MA50942A (fr) Protéines de liaison à l'adn modifiées
MA46534A (fr) Protéines de fusion fc hétérodimères il15/il15r
DK3582806T3 (da) Proteiner, der binder her2, nkg2d og cd16
IL272553A (en) Proteins that bind D2NKG, 16CD, and EGFR, E-HLA, 4CCR, or 1L-PD
DK3275895T3 (da) Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf
EP3630183A4 (fr) Protéine de liaison à nkg2d, cd16 et ror1 ou ror2
IL281323A (en) Proteins that bind D2NKG, 16CD, and tumor-associated antigen
DK3425046T3 (da) Herbicidtolerant protein, kodningsgen og anvendelse deraf
MA42059A (fr) Agents de liaison bispécifique à l'antigène membranaire spécifique de la prostate (psma) et utilisations de ceux-ci
DK3253795T3 (da) Hidtil ukendte bindende proteiner, der omfatter et ubiquitin-mutein, og antistoffer eller antistoffragmenter
MA42821A (fr) Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci
MA47113A (fr) Protéines de liaison à l'antigène anti- neuropiline et leurs méthodés d'utilisation
DK3830120T3 (da) Hidtil ukendt fusionsprotein specifikt for cd137 og pd-l1
EP3689893A4 (fr) Protéine de liaison à l'immunoglobuline, et support d'affinité mettant en uvre celle-ci
MA49769A (fr) Protéines se liant à nkg2d, cd16 et flt3
IL272706A (en) Proteins that bind D2NKG, 16CD, and tumor-associated antigen
IL268768A (en) Proteins binding gd2, nkg2d and cd16
IL276616A (en) Dosage for treatment with IL-22 Fc fusion proteins
EP3579878A4 (fr) Protéines fixant le psma, le nkg2d et le cd16
MA46844A (fr) Protéines de liaison à un antigène anti-gitr et leurs procédés d'utilisation